BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

...Phase III testing for cutaneous T cell lymphoma (CTCL). D. Western Therapeutics Institute Inc. and Wakamoto Pharmaceutical Co. Ltd....
BioCentury | Apr 11, 2016
Clinical News

WP-1303: Phase I started

...in Japan (see BioCentury, May 20, 2013). D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Wakamoto Pharmaceutical Co. Ltd....
BioCentury | May 20, 2013
Company News

D. Western, Wakamoto Pharmaceutical deal

...testing is expected to start this year. D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Wakamoto Pharmaceutical Co. Ltd....
Items per page:
1 - 3 of 3
BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

...Phase III testing for cutaneous T cell lymphoma (CTCL). D. Western Therapeutics Institute Inc. and Wakamoto Pharmaceutical Co. Ltd....
BioCentury | Apr 11, 2016
Clinical News

WP-1303: Phase I started

...in Japan (see BioCentury, May 20, 2013). D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Wakamoto Pharmaceutical Co. Ltd....
BioCentury | May 20, 2013
Company News

D. Western, Wakamoto Pharmaceutical deal

...testing is expected to start this year. D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Wakamoto Pharmaceutical Co. Ltd....
Items per page:
1 - 3 of 3